These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 10579828)

  • 21. Cholecystokinin dipeptoid antagonists: design, synthesis, and anxiolytic profile of some novel CCK-A and CCK-B selective and "mixed" CCK-A/CCK-B antagonists.
    Boden PR; Higginbottom M; Hill DR; Horwell DC; Hughes J; Rees DC; Roberts E; Singh L; Suman-Chauhan N; Woodruff GN
    J Med Chem; 1993 Mar; 36(5):552-65. PubMed ID: 7684452
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Photoaffinity labeling of rat pancreatic cholecystokinin type A receptor antagonist binding sites demonstrates the presence of a truncated cholecystokinin type A receptor.
    Poirot SS; Escrieut C; Dufresne M; Martinez J; Bouisson M; Vaysse N; Fourmy D
    Mol Pharmacol; 1994 Apr; 45(4):599-607. PubMed ID: 8183238
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CCK-B agonist or antagonist activities of structurally hindered and peptidase-resistant Boc-CCK4 derivatives.
    Corringer PJ; Weng JH; Ducos B; Durieux C; Boudeau P; Bohme A; Roques BP
    J Med Chem; 1993 Jan; 36(1):166-72. PubMed ID: 8421283
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological profile of TP-680, a new cholecystokininA receptor antagonist.
    Akiyama T; Tachibana I; Hirohata Y; Shirohara H; Yamamoto M; Otsuki M
    Br J Pharmacol; 1996 Apr; 117(7):1558-64. PubMed ID: 8730754
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CCK(2) receptor antagonists containing the conformationally constrained phenylalanine derivatives, including the new amino acid Xic.
    Gibson SE; Guillo N; Jones JO; Buck IM; Kalindjian SB; Roberts S; Tozer MJ
    Eur J Med Chem; 2002 May; 37(5):379-89. PubMed ID: 12008052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Binding of cholecystokinin-8 (CCK-8) peptide derivatives to CCKA and CCKB receptors.
    Schäfer U; Harhammer R; Boomgaarden M; Sohr R; Ott T; Henklein P; Repke H
    J Neurochem; 1994 Apr; 62(4):1426-31. PubMed ID: 8133271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological properties of ureido-acetamides, new potent and selective non-peptide CCKB/gastrin receptor antagonists.
    Bertrand P; Böhme GA; Durieux C; Guyon C; Capet M; Jeantaud B; Boudeau P; Ducos B; Pendley CE; Martin GE
    Eur J Pharmacol; 1994 Sep; 262(3):233-45. PubMed ID: 7813588
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carboxylic acids and tetrazoles as isosteric replacements for sulfate in cholecystokinin analogues.
    Tilley JW; Danho W; Lovey K; Wagner R; Swistok J; Makofske R; Michalewsky J; Triscari J; Nelson D; Weatherford S
    J Med Chem; 1991 Mar; 34(3):1125-36. PubMed ID: 2002454
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Boc-Trp-Orn(Z)-Asp-NH2 and derivatives: a new family of CCK antagonists.
    Gonzalez-Muniz R; Bergeron F; Marseigne I; Durieux C; Roques BP
    J Med Chem; 1990 Dec; 33(12):3199-204. PubMed ID: 1701834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ac-[3- and 4-alkylthioproline31]-CCK4 analogs: synthesis and implications for the CCK-B receptor-bound conformation.
    Kolodziej SA; Nikiforovich GV; Skeean R; Lignon MF; Martinez J; Marshall GR
    J Med Chem; 1995 Jan; 38(1):137-49. PubMed ID: 7837225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of 1,4-benzodiazepine cholecystokinin type B antagonists.
    Bock MG; DiPardo RM; Evans BE; Rittle KE; Whitter WL; Garsky VM; Gilbert KF; Leighton JL; Carson KL; Mellin EC
    J Med Chem; 1993 Dec; 36(26):4276-92. PubMed ID: 8277510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biological effects of newly synthesized cholecystokinin analogs.
    Verspohl EJ; LaMura M
    Horm Res; 2000; 53(4):177-84. PubMed ID: 11044801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modification of receptor selectivity and functional activity in cholecystokinin peptoid ligands.
    Dezube M; Sugg EE; Birkemo LS; Croom DK; Dougherty RW; Ervin GN; Grizzle MK; James MK; Johnson MF; Mosher JT
    J Med Chem; 1995 Aug; 38(17):3384-90. PubMed ID: 7650691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis, biological evaluation, and quantitative receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as novel tifluadom-like ligands with high affinity and selectivity for kappa-opioid receptors.
    Cappelli A; Anzini M; Vomero S; Menziani MC; De Benedetti PG; Sbacchi M; Clarke GD; Mennuni L
    J Med Chem; 1996 Feb; 39(4):860-72. PubMed ID: 8632410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alteration of cholecystokinin receptor binding after caerulein-induced pancreatitis in rats.
    Yazu T; Kimura T; Sumii T; Nawata H
    Digestion; 1991; 50(3-4):142-8. PubMed ID: 1725866
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Second generation "peptoid" CCK-B receptor antagonists: identification and development of N-(adamantyloxycarbonyl)-alpha-methyl-(R)-tryptophan derivative (CI-1015) with an improved pharmacokinetic profile.
    Trivedi BK; Padia JK; Holmes A; Rose S; Wright DS; Hinton JP; Pritchard MC; Eden JM; Kneen C; Webdale L; Suman-Chauhan N; Boden P; Singh L; Field MJ; Hill D
    J Med Chem; 1998 Jan; 41(1):38-45. PubMed ID: 9438020
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biological properties of the benzodiazepine amidine derivative L-740,093, a cholecystokinin-B/gastrin receptor antagonist with high affinity in vitro and high potency in vivo.
    Patel S; Smith AJ; Chapman KL; Fletcher AE; Kemp JA; Marshall GR; Hargreaves RJ; Ryecroft W; Iversen LL; Iversen SD
    Mol Pharmacol; 1994 Nov; 46(5):943-8. PubMed ID: 7969084
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CCK-A receptor selective antagonists derived from the CCK-A receptor selective tetrapeptide agonist Boc-Trp-Lys(Tac)-Asp-MePhe-NH2 (A-71623).
    Sugg EE; Kimery MJ; Ding JM; Kenakin DC; Miller LJ; Queen KL; Rimele TJ
    J Med Chem; 1995 Jan; 38(1):207-11. PubMed ID: 7837233
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Melatonin precursor; L-tryptophan protects the pancreas from development of acute pancreatitis through the central site of action.
    Leja-Szpak A; Jaworek J; Tomaszewska R; Nawrot K; Bonior J; Kot M; Palonek M; Stachura J; Czupryna A; Konturek SJ; Pawlik WW
    J Physiol Pharmacol; 2004 Mar; 55(1 Pt 2):239-54. PubMed ID: 15082881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and binding affinities of analogues of cholecystokinin-(30-33) as probes for central nervous system cholecystokinin receptors.
    Horwell DC; Beeby A; Clark CR; Hughes J
    J Med Chem; 1987 Apr; 30(4):729-32. PubMed ID: 3560164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.